Workflow
仙琚制药(002332) - 2022 Q1 - 季度财报
XJZYXJZY(SZ:002332)2022-04-26 16:00

Revenue and Profitability - The company's revenue for Q1 2022 was ¥1,049,027,960.34, representing a 4.76% increase compared to ¥1,001,363,720.40 in the same period last year[3] - Net profit attributable to shareholders was ¥127,713,332.35, up 15.47% from ¥110,602,233.70 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥126,262,345.28, reflecting a 16.26% increase from ¥108,605,653.74 in the previous year[3] - Total operating revenue for the current period reached ¥1,049,027,960.34, an increase of 4.8% compared to ¥1,001,363,720.40 in the previous period[21] - Net profit for the current period was ¥122,094,681.17, compared to ¥112,589,627.22 in the previous period, representing an increase of 8.9%[24] - The net profit attributable to the parent company was ¥127,713,332.35, up from ¥110,602,233.70, marking a growth of 15.4%[27] - The total comprehensive income for the current period was ¥108,595,308.92, compared to ¥93,002,355.96 in the previous period, reflecting an increase of 16.8%[27] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 90.81%, amounting to ¥5,935,810.00 compared to ¥64,571,088.88 in the same period last year[3] - The net cash flow from operating activities was 5,935,810.00, a significant decrease from 64,571,088.88 in the previous period, indicating a decline in operational efficiency[30] - Cash inflow from operating activities totaled 926,986,324.31, while cash outflow was 921,050,514.31, resulting in a narrow margin of cash generation[30] - The net cash flow from investing activities was -63,740,310.49, compared to -15,785,339.55 previously, reflecting increased investment expenditures[33] - Cash inflow from financing activities was 110,800,000.00, down from 245,653,380.25, indicating reduced capital raising efforts[33] - The net cash flow from financing activities improved to 34,664,410.03 from -12,153,374.42, suggesting better management of financing costs[33] - The ending balance of cash and cash equivalents was 1,108,175,110.49, down from 1,242,588,429.15, showing a decrease in liquidity[33] - The company received 1,804,013.95 in tax refunds, a decrease from 8,056,092.18, indicating a potential decline in tax efficiency[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,835,092,522.06, a 1.66% increase from ¥6,723,208,000.32 at the end of the previous year[3] - Shareholders' equity attributable to the parent company increased by 2.37% to ¥4,943,442,072.27 from ¥4,829,228,112.17 at the end of the previous year[3] - The total liabilities amounted to ¥1,781,605,150.92, slightly up from ¥1,778,315,938.10, indicating a marginal increase of 0.1%[19] - Total equity increased to ¥5,053,487,371.14 from ¥4,944,892,062.22, reflecting a growth of 2.2%[19] - Total current liabilities amounted to approximately CNY 1.40 billion, up from CNY 1.39 billion, indicating a growth of about 0.97%[16] Investments and Expenses - Research and development expenses for the current period were ¥57,373,399.37, compared to ¥51,854,252.28 in the previous period, showing an increase of 10.0%[24] - The company reported a notable increase in accounts payable, which stood at approximately CNY 299.57 million, down from CNY 310.60 million, a decrease of about 3.34%[16] - Cash outflow for investment activities rose significantly to 64,846,177.89 from 15,802,784.22, indicating aggressive investment strategies[33] - The company reported a cash inflow of 831,250.00 from other investment activities, highlighting additional revenue streams[33] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 47,370[8]